LEGEND: A randomised phase II study comparing lenalidomide plus rituximab, gemcitabine, and methylprednisolone (R-GEM-L) to rituximab, gemcitabine, methylprednisolone, and cisplatin (R-GEM-P) in second-line treatment of diffuse large B-cell lymphoma (DLBCL).

Authors

Gleeson M; Chau I; Peckitt C; Patel B; Wotherspoon A; Attygalle A; Du Y; Sharma B; Cunningham D

Journal of Clinical Oncology, Vol. 32, No. 15_suppl, pp. tps8618–tps8618

American Society of Clinical Oncology (ASCO)

May 20, 2014

10.1200/jco.2014.32.15_suppl.tps8618

0732-183X

Yong Du